Boston Scientific Prices $3B USD and €4.25B Euro Note Offerings
1 report, 1 independent
Updated Nov 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Boston Scientific Corporation announced two public offerings of notes. The company priced a $3 billion USD offering, consisting of various senior notes due between 2029 and 2036. Additionally, American Medical Systems Europe B.V., a subsidiary, priced a €4.25 billion Euro offering, which includes notes due up to 2046.
From prnewswire.com
Why it matters
The dual financing efforts provide Boston Scientific with substantial capital. This funding occurs within the context of the company's $14.5 billion acquisition of Penumbra, which also gained clearance for its Thunderbolt product line.
Penumbra was acquired by Boston Scientific in a $14.5 billion deal, and the company gained clearance for its Thunderbolt product line.
From prnewswire.com
Who's involved
- Edwards LifesciencesA competitor in the medical technology sector